Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study)

. 2015 Jan ; 36 (1) : 14-23. [epub] 20141009

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid25300984

BACKGROUND AND PURPOSE: Gadobutrol (Gadavist) and gadoteridol (ProHance) have similar macrocyclic molecular structures, but gadobutrol is formulated at a 2-fold higher (1 mol/L versus 0.5 mol/L) concentration. We sought to determine whether this difference impacts morphologic contrast-enhanced MR imaging. MATERIALS AND METHODS: Two hundred twenty-nine adult patients with suspected or known brain tumors underwent two 1.5T MR imaging examinations with gadoteridol or gadobutrol administered in randomized order at a dose of 0.1 mmol/kg of body weight. Imaging sequences and T1 postinjection timing were identical for both examinations. Three blinded readers evaluated images qualitatively and quantitatively for lesion detection and for accuracy in characterization of histologically confirmed brain tumors. Data were analyzed by using the Wilcoxon signed rank test, the McNemar test, and a mixed model. RESULTS: Two hundred nine patients successfully completed both examinations. No reader noted a significant qualitative or quantitative difference in lesion enhancement, extent, delineation, or internal morphology (P values = .69-1.00). One hundred thirty-nine patients had at least 1 histologically confirmed brain lesion. Two readers found no difference in the detection of patients with lesions (133/139 versus 135/139, P = .317; 137/139 versus 136/139, P = .564), while 1 reader found minimal differences in favor of gadoteridol (136/139 versus 132/139, P = .046). Similar findings were noted for the number of lesions detected and characterization of tumors (malignant/benign). Three-reader agreement for characterization was similar for gadobutrol (66.4% [κ = 0.43]) versus gadoteridol (70.3% [κ = 0.45]). There were no significant differences in the incidence of adverse events (P = .199). CONCLUSIONS: Gadoteridol and gadobutrol at 0.1 mmol/kg of body weight provide similar information for visualization and diagnosis of brain lesions. The 2-fold higher gadolinium concentration of gadobutrol provides no benefit for routine morphologic imaging.

Zobrazit více v PubMed

Gadavist product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdf. Accessed April 11, 2014.

ProHance product label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020131s024lbl.pdf. Accessed April 11, 2014.

Hao D, Ai T, Goerner F, et al. . MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012;36:1060–71 PubMed

Rohrer M, Bauer H, Mintorovitch J, et al. . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715–24 PubMed

Pintaske J, Martirosian P, Graf H, et al. . Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213–21 PubMed

Koenig M, Schulte-Altedorneburg G, Piontek M, et al. . Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read. Eur Radiol 2013;23:3287–95 PubMed

Lopes MB, VandenBerg SR, Scheithauer BW. The World Health Organization classification of nervous system tumors in experimental neuro-oncology. In: Levine AJ, Schmidek HH, eds. Molecular Genetics of Nervous System Tumors. New York: Wiley-Liss; 1993:1–36

Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993;3:255–68 PubMed

Katakami N, Inaba Y, Sugata S, et al. . Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0M compared with gadoteridol: a multicenter, phase II/III study in patients with known or suspected brain metastases. Invest Radiol 2011;46:411–18 PubMed

Peripheral and Central Nervous System Drugs Advisory Committee. FDA Advisory Committee Briefing Document. New Drug Application 201–277. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM240354.pdf. Accessed May 8, 2014.

Center for Drug Evaluation and Research. Statistical Review and Evaluation. Gadovist. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM255169.pdf. Accessed May 8, 2014.

Heiland S, Erb G, Ziegler S, Krix M. Where contrast agent concentration really matters: a comparison of CT and MRI. Invest Radiol 2010;45:529–37 PubMed

Kanal E, Maravilla K, Rowley HA. Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol 2014;35:2215–26 PubMed PMC

Greco A, Parker JR, Ratcliffe CG, et al. . Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 2001;45:457–63 PubMed

Anzalone N, Scarabino T, Venturi C, et al. . Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1mmolGd/kg body weight in a clinical setting. Eur J Radiol 2013;82:139–45 PubMed

Seidl Z, Vymazal J, Mechl M, et al. . Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol 2012;33:1050–58 PubMed PMC

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...